

## INTRODUCTION

**D**ermatology has evolved into one of the most dynamic specialties in medicine. Advances in cellular and molecular biology have translated into clinical progress in the management of multiple conditions that dermatologists treat.

The progress has increased the educational demands of dermatologists to remain up to date regarding the latest developments in the field. The Hawaii Dermatology Seminar offers dermatologists an opportunity to improve their understanding and application of the latest developments in the specialty, regardless of whether their interests lie in skin disease, oncology, or aesthetic dermatology.

This supplement provides a concise yet thorough summation of presentations at the seminar. Leading authorities in the management of psoriasis, skin cancer, and rejuvenation treatment share their expertise and insights that dermatologists will find readily applicable to clinical practice.

Dr Brian F. Mandell and Dr Jeffrey M. Sobell review the role of tumor necrosis factor (TNF) inhibitors in the treatment of psoriatic disease and its comorbidities and offer authoritative insight into new biologic therapies for the disease. Dr Craig L. Leonardi examines the process of evaluating the safety of psoriasis therapies and reviews new nonbiologic systemic therapies for psoriasis.

Dr Brian F. Mandell shares what rheumatologists have learned about the use of anti-TNF therapies, focusing on issues that apply equally to dermatologists.

Dr James E. Sligh summarizes recent developments in the management of actinic keratosis and basal cell carcinoma.

Finally, leading authorities in aesthetic dermatology discuss the use of hyaluronic acid fillers for treatment of age-related skin changes affecting the face. The contributions are by Dr Sue Ellen Cox, Dr Mark G. Rubin, Dr Michael S. Kaminer, and Dr Nowell Solish. They provide insights gained from extensive clinical experience in the treatment of the upper face, midface, lower face, and tear troughs. Additionally, Dr Rubin discusses the role of neurotoxins in facial rejuvenation. Video highlights of SDEF's 38th Hawaii Dermatology Seminar will also be available at [www.globalacademycme.com/index.php?id=8656](http://www.globalacademycme.com/index.php?id=8656).

Craig L. Leonardi, MD  
Clinical Professor of Dermatology  
Saint Louis University  
Central Dermatology  
St Louis, Missouri  
*Journal Supplement Chair*

---

Publication of this CME article was jointly sponsored by the University of Louisville School of Medicine Continuing Medical Education and Global Academy for Medical Education, LLC, and is supported by educational grants from AbbVie, Inc., Eli Lilly and Company, Genentech, Inc., Merz, Inc., and Novartis Pharmaceuticals Corporation.

Dr Leonardi has received an honorarium from Global Academy for Medical Education for his participation in this activity. He acknowledges the editorial assistance of Charles Bankhead, medical writer, and Global Academy for Medical Education in the development of this continuing medical education journal article. Charles Bankhead has no relevant financial relationships with any commercial interests.

---

Craig L. Leonardi, MD, has been a consultant and/or investigator and/or speaker and/or advisory board member for AbbVie, Amgen Inc., Anacor Pharmaceuticals, Inc., Celgene Corporation, Janssen Biotech, Inc., Eli Lilly, Galderma Laboratories, L.P., GlaxoSmithKline, Incyte Corporation, LEO Pharma Inc., Maruho Co., Ltd., Novartis, Novo Nordisk, Inc., Pfizer Inc., Schering-Plough Corporation, Sirtis Pharmaceuticals, Inc., Stiefel Laboratories, Inc., TOLMAR Pharmaceuticals, Inc., Vascular Biogenics Ltd., and Warner Chilcott plc.

1085-5629/13/\$-see front matter © 2014 Frontline Medical Communications  
DOI: 10.12788/j.sder.0096